by GlyTherix | Dec 10, 2024
GlyTherix and Nusano, a physics company transforming the production of radioisotopes, today announced a supply agreement for non-carrier-added lutetium-177 (Lu-177). The agreement also provides GlyTherix access to Nusano’s future actinium-225 (Ac-225) production,...
by GlyTherix | Sep 10, 2024
GlyTherix Ltd is pleased to announce the execution of a Master Service Agreement with 3D Imaging LLC (3DI), a Contract Development and Manufacturing Organization (CDMO), for the manufacture of GlyTherix’s targeted radiotherapy antibody products for its US clinical...
by GlyTherix | Oct 10, 2023
Sydney, Australia – 10 Oct 2023. GlyTherix Ltd (GlyTherix), an Australian immuno-oncology company specialising in developing antibody radiopharmaceuticals for solid tumours is pleased to announce that it has entered into a Collaborative Research Agreement with the...
by GlyTherix | Feb 21, 2023
ANSTO to supply Lutetium-177 for GlyTherix’s Phase Ib therapeutic trial in patients with prostate, pancreatic and bladder cancers Phase Ib basket clinical trial expected to start in late 2023 Sydney, Australia – February 21, 2023 – GlyTherix Ltd, an Australian...
by GlyTherix | Sep 8, 2022
GlyTherix Ltd today announces that it has been jointly awarded a $4.8 million Australian Research Council (ARC) grant to establish a new Industrial Transformation Research Program (ITRP) Hub as part of a consortium of applicants led by The University of Queensland....
by GlyTherix | Jul 21, 2022
Date, July 21 2022: Sydney. GlyTherix is pleased to announce the successful completion of its high-yield GMP-grade stable cell line development program for its proprietary antibody Miltuximab® in partnership with international biologics manufacturer GenScript ProBio...
